查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853299

人類抗菌藥物敏感性檢測市場（按產品、技術、檢測類型、應用、最終用戶和病原體分類）—全球預測，2025-2032年

Human Antimicrobial Susceptibility Testing Market by Product, Technology, Test Type, Application, End User, Pathogen - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人類抗菌藥物敏感性測試市場規模將成長 63 億美元，複合年成長率為 6.10%。

關鍵市場統計數據
基準年 2024 39.2億美元
預計年份：2025年 41.6億美元
預測年份 2032 63億美元
複合年成長率 (%) 6.10%

本書以強力的導論形式，概述了正在重塑全球抗菌藥物敏感性試驗實踐的臨床、操作和技術因素。

人類抗菌藥物敏感性檢測領域正曲折點，其促進因素包括臨床需求的匯聚、實驗室工作流程的演變以及技術的加速成熟。由於多重抗藥性病菌感染、抗藥性機制以及對快速有效結果的需求，臨床團隊面臨日益複雜的診斷挑戰，這就要求藥敏試驗結果既可靠又要快速。同時，研發和製藥合作夥伴對標準化、可重複的檢測平台的需求也在不斷成長，這些平台能夠整合到藥物開發平臺和轉換研究中。

實驗室面臨許多相互衝突的優先事項，包括維持合規性、縮短週轉時間以及最佳化試劑和設備的利用率，同時還要應對預算限制和熟練勞動力短缺的問題。這些營運現實正在重塑採購標準，並將重點轉向能夠提供自動化、互聯互通以及針對不同檢體類型檢驗的效能的系統。先進的分子和表現型混合工作流程的採用，正在重新定義藥敏試驗（AST）的角色，使其成為鑑定和治療管理之間的橋樑。

在這些壓力之下，相關人員必須平衡短期臨床需求與長期策略投資。臨床醫生、微生物學家、資訊科技專業人員和採購團隊之間的跨職能協作對於將診斷資訊轉化為改善患者預後至關重要。本導言闡述了重要的背景資訊和關鍵的變革方向，為後續章節的詳細分析奠定了基礎。

明確技術和商業性轉型方向，以加速藥敏試驗工作流程中的自動化、分子雜合反應和軟體整合。

抗菌藥物敏感性檢測領域正經歷著一場變革性的轉變，這場變革由自動化、分子整合和軟體驅動的決策支援所驅動。自動化系統正逐步減少人工實驗室的工作時間和操作差異，使實驗室能夠在無需相應增加人員的情況下擴大生產能力。這項變革得益於能夠整合結果、進行趨勢分析並提供以抗菌藥物管理為導向的報告的軟體平台。

分子檢測技術的同步發展使得標靶檢測抗藥性決定簇成為可能，從而補充了表現型藥敏試驗的結果。結合快速分子篩檢和表現型確證檢測的混合工作流程正在成為兼顧速度和臨床相關性的實用解決方案。此外，試劑和耗材的創新，例如預拌培養基、穩定條和試劑套件，正在簡化常規工作流程，並提高分散式檢測環境中的可重複性。

供應商正優先考慮可互通的平台、開放資料標準以及超越傳統資本銷售、轉向基於耗材和資料主導收入流的服務模式。因此，臨床實驗室和研究機構必須調整其採購、檢驗和IT整合方法，才能充分發揮這些創新技術的潛力。

評估2025年生效的美國關稅調整對檢測採購和實驗室連續性的累積營運和供應鏈影響。

2025年關稅措施和貿易政策調整的實施，對參與抗菌藥物敏感性測試的實驗室、製造商和分銷網路產生了複雜的下游影響。關鍵進口設備、試劑和組件的進口關稅增加以及監管摩擦加劇，導致採購前置作業時間延長，並促使採購團隊重新評估總到岸成本。因此，供應鏈規劃已從週期性採購轉向持續風險規避和多源採購策略。

製造商已採取應對措施，重新評估其全球生產佈局，增加受關稅影響地區的在地化生產，並重新配置供應鏈網路以降低成本波動。這些轉變改變了庫存緩衝、關鍵耗材策略儲備以及與經銷商合約條款的決策。對於實驗室而言，這些轉變也帶來了一些實際影響，例如新採購產品的驗證期延長、潛在的替代品需要進行交叉驗證，以及對供應商服務模式進行嚴格審查，以確保過渡期間檢測能力的持續性。

展望未來，持續的關稅主導的供應中斷可能會增強區域供應鏈的韌性，並推動對國內試劑和儀器生產的投資。同時，相關人員應密切注意監管協調工作和貿易談判，以期緩解摩擦。在此背景下，靈活的籌資策略、加強供應商合作以及前瞻性的驗證通訊協定對於維持檢測的連續性和臨床可靠性至關重要。

透過對產品、技術、測試類型、應用、最終用戶和病原體等領域的綜合細分洞察，揭示了實際的採購和驗證需求。

細緻的細分框架揭示了臨床需求、技術能力和採購行為在產品、技術、檢測類型、應用、最終用戶和病原體等維度上的交集。產品差異化包括儀器、試劑/耗材和軟體，其中儀器又細分為桌上型和全自動兩種類型，試劑/耗材則細分為光碟、套件、培養基和試紙條。這種產品層面的細分體現在採購優先順序：桌上型平台通常優先考慮在地化和靈活性，而全自動系統則優先考慮吞吐量和整合性。

技術領域涵蓋自動化系統、紙錠擴散法、梯度試紙條法、微量稀釋法和分子生物學方法。在自動化系統中，平台層面的差異——MicroScan 型、Phoenix 型和完全整合的 Vitek 型——決定了互通性和實驗室工作流程的重新設計。自動化測試和手動測試（手動方法包括瓊脂稀釋法、肉湯晶粒、紙片擴散法和梯度試紙條法）之間的測試類型差異凸顯了分析精度和操作可擴展性之間的權衡。應用範圍從臨床診斷到藥物開發和研究，每種應用場景都對驗證的嚴謹性、可追溯性和數據整合提出了獨特的要求。

包括診所、診斷實驗室、醫院和研究機構在內的終端用戶，各自面臨不同的吞吐量需求、資金限制和監管要求，這些因素都會影響產品和技術的採用頻譜。病原體分類，例如真菌、革蘭氏陰性菌、革蘭氏陽性菌和分枝桿菌，以及革蘭氏陰性菌的亞分類，例如腸桿菌科和非腸桿菌科，都會影響試劑配方需求、結果判讀標準和藥敏終點決策。了解這些相互依存的細分層面，有助於相關人員確定投資優先順序並協調營運藍圖。

關鍵區域洞察揭示了法律規範、基礎設施投資和製造業動態如何影響美洲、歐洲、中東和非洲以及亞太地區的採用。

在美洲、歐洲、中東和非洲以及亞太地區，區域動態正在重塑採購偏好、監管互動以及技術創新的傳播。在美洲，對快速診斷的重視以及集中式檢測網路的整合，推動了對高通量自動化平台和整合資訊學的需求，以支援相關管理舉措。該地區的實驗室越來越注重快速週轉和可擴展性，以應對複雜的病例量，這影響著他們對設備和耗材的選擇。

歐洲、中東和非洲是一個異質性區域，監管協調工作、公共衛生優先事項和財政限制導致了不同的應用模式。在部分地區，嚴格的監管路徑和集中採購模式有利於採用檢驗的標準化解決方案。亞太地區在不斷擴大的國內生產能力和對實驗室基礎設施的大力投資的支持下，正迅速採用自動化和分子混合方法。該地區的規模和生產密度也使其成為供應鏈重組和試劑本地化的重點區域。

在所有地區，當地的法規結構、報銷模式和勞動力供應情況將繼續影響技術採納率，並影響供應商的策略。清楚了解每個地區的優先事項至關重要，這有助於制定符合各地區實驗室營運和臨床管治的市場准入、服務模式和經銷夥伴。

分析供應商優先考慮互通性、基於耗材的服務模式和監管合規性的策略，以增強其臨床和商業地位。

抗生素敏感性檢測生態系統中的主要企業日益重視平台互通性、基於耗材的服務模式以及支持臨床決策和抗生素管理目標的數據分析。供應商透過整合與實驗室資訊系統的連接、自動化結果解讀報告以及提供生命週期服務來增強其價值提案，從而減輕最終用戶的檢驗負擔。這些策略舉措優先考慮與臨床網路建立長期夥伴關係，而非一次性的儀器銷售。

試劑創新，例如穩定試劑套件和簡化培養基配方，也正在推動競爭差異化，這些創新能夠降低變異性並提高在不同實驗室環境下的儲存穩定性。製造商正在投資模組化系統，以實現逐步升級，從而在保護資本投資的同時，提高檢測通量並擴展檢測項目。儀器供應商和分子檢測開發人員之間的策略聯盟正在加速混合工作流程的發展，從而能夠快速將抗藥性決定簇的檢測結果轉化為可操作的藥敏性指導。

最後，各公司越來越重視監管合規和本地化支持，他們認知到快速的服務響應和健全的上市後監測對於臨床信心至關重要。產品創新、服務導向和監管嚴格性的結合，塑造了市場的競爭格局，並影響醫院、參考實驗室和研究機構的採購和夥伴關係選擇。

供應商和實驗室將提出切實可行的策略建議，以增強其整個藥敏試驗流程的韌性、互通性和臨床影響力。

產業領導者應採取平衡策略，在推進自動化和分子整合的同時，保持對人工操作和分散式檢測場景的靈活性。優先投資模組化、可互通的平台，能夠幫助實驗室在無需巨額資本支出的情況下擴展檢測能力。同時，與區域試劑生產商和經銷商建立牢固的夥伴關係，可以增強供應韌性，並降低對單一來源供應鏈的依賴。

在營運層面，將數據分析和以管理為導向的報告融入平台設計，可以提升臨床影響力並支持醫院管治目標的實現。供應商和實驗室都應攜手合作，共同規範資料格式，並採用便於與電子健康記錄和感染控制系統整合的應用程式介面（API）。從監管和品質角度來看，透過預先核准的方案和統一的方法比較研究來加速驗證流程，可以縮短部署時間，並確保在不同環境下效能的一致性。

最後，相關人員應採取動態採購方式，將整體擁有成本、服務應對力和驗證負擔納入採購決策。透過將商業模式與臨床工作流程和長期支援承諾相結合，行業領導者可以實現永續推廣和改善患者預後，同時減少營運和供應鏈中斷。

採用透明的混合方法研究途徑，結合文獻回顧、主要相關人員訪談和資料交叉檢驗三角測量，確保分析的嚴謹性。

調查方法結合了系統性的二手資料收集、有針對性的原始研究以及嚴謹的資料三角驗證，以確保得出可靠且可重複的結論。二手資料收集工作包括對同行評審文獻、監管指導文件、技術白皮書和公共採購政策進行結構化審查，以建立關於技術能力、測試標準和監管機構期望的基準事實。這個基礎層面有助於建構關鍵的交互假設和分析假設。

主要研究包括對實驗室主任、臨床微生物學家、採購負責人和行業高管進行結構化訪談，以了解營運實踐、採購促進因素和供應商績效認知。這些訪談旨在探討驗證實務、試劑處理、工作流程限制和售後服務期望。訪談內容經過編碼和綜合分析，以識別反覆出現的主題、區域差異和營運痛點，並最終提出切實可行的建議。

透過交叉驗證，對定量和定性輸入資料進行三角檢驗，以確保資料的一致性並識別異常值。調查方法品管包括可重複性檢查、分析師同行評審以及記錄資料來源的審核追蹤。這種混合方法有助於得出可靠的結論，並為臨床、研究和商業相關人員提供切實可行的指導。

簡明扼要的結論總結了指導永續藥敏試驗推廣和臨床整合的技術、操作和監管方面的必要條件。

總之，抗菌藥物敏感性檢測正從一項獨立的實驗室活動發展成為一項綜合性的臨床資源，為快速治療決策、舉措計劃和轉化研究提供支持。技術進步，特別是自動化、分子混合工作流程和軟體驅動報告的進步，在提高效率和臨床價值的同時，也為驗證、採購和供應鏈管理帶來了複雜性。相關人員必須謹慎權衡這些利弊，在速度、準確性和營運可行性之間取得平衡。

監管動態、區域製造業趨勢和不斷變化的貿易政策，都為採購、服務模式和供應商選擇增添了許多策略考量。成功的企業將投資於可互通的平台，維持多元化的供應關係，將數據分析融入臨床工作流程，並展現出可衡量的影響。臨床、實驗室和商業部門之間的協作對於將技術可能性轉化為可靠的日常實踐至關重要。

最終，務實的實驗、嚴格的檢驗以及與最終用戶的持續互動，對於確保易感性檢測的創新能夠改善患者預後並加強公共衛生準備至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用微流體晶片技術擴大即時快速敏感度檢測的規模
  • 利用人工智慧驅動的解釋演算法來提高抗菌藥物敏感性試驗結果的準確性
  • 抗菌藥物管理計劃日益重要，推動了對快速抗菌藥物敏感性試驗解決方案的需求。
  • 自動化、高通量表現型易感性檢測設備的商業化
  • 新型抗生素敏感性檢測生物標記和檢測方法的監管核准
  • 將即時雲端基礎數據分析整合到臨床抗菌藥物敏感性試驗（AST）工作流程中，以支援決策。
  • 開發可攜式連接複用AST設備
  • 加大對基於次世代定序的抗藥性分析在臨床診斷上的投資

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 人類抗菌藥物敏感性測試市場（依產品分類）

  • 裝置
    • 工作台
    • WalkAway
  • 試劑耗材
    • 磁碟
    • 套件
    • 媒體
    • 條
  • 軟體

9. 按技術分類的人類抗菌藥物敏感性檢測市場

  • 自動化系統
    • 微型掃描系統
    • 鳳凰系統
    • Vitec Systems
  • 盤狀擴散
  • 漸變條
  • 微量稀釋法
  • 分子方法

10. 按檢測類型分類的人類抗菌藥物敏感性檢測市場

  • 自動化測試
  • 手動測試
    • 瓊脂稀釋法
    • 肉湯微量稀釋法
    • 盤狀擴散
    • 漸變條

第11章：按應用分類的人類抗菌藥物敏感性測試市場

  • 臨床診斷
  • 製藥
  • 研究

12. 按最終用戶分類的人類抗菌藥物敏感性測試市場

  • 診所
  • 診斷實驗室
  • 醫院
  • 研究所

13. 依病原體分類的人類抗菌藥物敏感性檢測市場

  • 真菌
  • 革蘭氏陰性菌
    • 腸桿菌科
    • 除腸桿菌科以外的細菌
  • 革蘭氏陽性菌
  • 抗酸桿菌

14. 各地區人類抗菌藥物敏感性檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 按組別分類的人類抗菌藥物敏感性檢測市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國人類抗菌藥物敏感性檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • bioMerieux SA
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company
    • Danaher Corporation
    • Siemens Healthineers AG
    • Accelerate Diagnostics Inc.
    • Bruker Corporation
    • QIAGEN NV
    • F. Hoffmann-La Roche AG
    • Luminex Corporation
Product Code: MRR-4E27A4DF1227

The Human Antimicrobial Susceptibility Testing Market is projected to grow by USD 6.30 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.92 billion
Estimated Year [2025] USD 4.16 billion
Forecast Year [2032] USD 6.30 billion
CAGR (%) 6.10%

High-impact introduction outlining the converging clinical, operational, and technological forces reshaping antimicrobial susceptibility testing practices globally

The landscape of human antimicrobial susceptibility testing is at an inflection point driven by converging clinical pressures, evolving laboratory workflows, and accelerating technology maturation. Clinical teams confront increasing diagnostic complexity as polymicrobial infections, resistance mechanisms, and the need for rapid actionable results demand both robustness and speed in susceptibility outputs. At the same time, research and pharmaceutical partners are intensifying their demand for standardized, reproducible testing platforms that can integrate with drug development pipelines and translational studies.

Laboratories face competing priorities: maintaining regulatory compliance, reducing turnaround times, and optimizing reagent and instrument utilization while managing constrained budgets and skilled workforce shortages. These operational realities are reshaping procurement criteria, shifting the emphasis toward systems that deliver automation, connectivity, and validated performance across diverse specimen types. The introduction of advanced molecular and phenotypic hybrid workflows is redefining the role of AST as a bridge between identification and therapeutic stewardship.

Given these pressures, stakeholders must reconcile near-term clinical imperatives with long-term strategic investments. Cross-functional collaboration among clinicians, microbiologists, informaticians, and procurement teams is essential to translate diagnostic intelligence into improved patient outcomes. This introduction establishes the critical context and the main vectors of change that inform the deeper analysis in subsequent sections

Defining transformative technological and commercial shifts that are accelerating automation, molecular hybridization, and software integration across susceptibility testing workflows

The field of antimicrobial susceptibility testing is undergoing transformative shifts driven by automation, molecular integration, and software-enabled decision support. Automated systems are progressively reducing manual hands-on time and variability, enabling laboratories to scale capacity without proportionally expanding headcount. This transformation is reinforced by software platforms that consolidate results, enable trend analysis, and provide stewardship-focused reporting-shifting AST from a standalone laboratory procedure to an integral part of clinical decision pathways.

Parallel advances in molecular methods are enabling targeted detection of resistance determinants that complement phenotypic susceptibility outputs. Hybrid workflows that combine rapid molecular screening with confirmatory phenotypic testing are emerging as pragmatic solutions that balance speed and clinical relevance. Additionally, reagent and consumable innovations-such as pre-formulated media, stabilized strips, and kit-based reagents-are simplifying routine workflows and improving reproducibility across decentralized testing environments.

These shifts are also catalyzing changes in commercial strategy: vendors are prioritizing interoperable platforms, open data standards, and service models that extend beyond capital sales into consumable-based and data-driven revenue streams. As a result, clinical laboratories and research organizations must adapt procurement, validation, and IT integration approaches to fully realize the potential of these transformative technologies

Assessing the cumulative operational and supply chain consequences of United States tariff changes implemented in 2025 on testing procurement and laboratory continuity

The introduction of tariff measures and trade policy adjustments in 2025 has created complex downstream effects for laboratories, manufacturers, and distribution networks involved in antimicrobial susceptibility testing. Increased import duties and regulatory friction on key imported instruments, reagents, and components have amplified procurement lead times and prompted procurement teams to reassess total landed costs. As a consequence, supply chain planning has moved from periodic purchasing toward continuous risk mitigation and multi-sourcing strategies.

Manufacturers have responded by reassessing their global manufacturing footprints, increasing local production in tariff-affected jurisdictions, and reconfiguring supply networks to mitigate cost volatility. These shifts have altered decisions about inventory buffering, strategic stockpiling of critical consumables, and contractual terms with distributors. For laboratories, the practical implications include extended validation timelines for newly sourced products, potential substitutions that require cross-validation, and closer scrutiny of vendor service models to ensure continuity in testing capabilities during transition periods.

Looking ahead, sustained tariff-driven disruption can incentivize regional supply resilience and spur investments in domestic reagent and instrument production. At the same time, stakeholders must monitor regulatory harmonization efforts and trade negotiations that could ease friction. In this environment, flexible procurement strategies, enhanced supplier collaboration, and forward-looking validation protocols will be essential to preserve testing continuity and clinical reliability

Integrated segmentation insights linking product, technology, test type, application, end-user, and pathogen dimensions to practical procurement and validation imperatives

A nuanced segmentation framework reveals where clinical need, technological capability, and procurement behavior intersect across product, technology, test type, application, end user, and pathogen dimensions. Product differentiation encompasses instruments, reagents and consumables, and software, with instruments subdivided by bench top and walk-away modalities and reagents and consumables including discs, kits, media, and strips-each category driving distinct validation, inventory, and cost considerations for laboratories. This product-level granularity informs procurement priorities: bench top platforms often emphasize local footprint and flexibility, whereas walk-away systems prioritize throughput and integration.

Technology segmentation spans automated systems, disk diffusion, gradient strip, microdilution, and molecular methods; within automation, platform-level differentiation between MicroScan-style, Phoenix-style, and fully integrated Vitek-style systems determines interoperability and laboratory workflow redesign. Test type distinctions between automated testing and manual testing-where manual approaches include agar dilution, broth microdilution, disk diffusion, and gradient strip-highlight trade-offs between analytical precision and operational scalability. Applications range from clinical diagnostics to pharmaceutical development and research, with each use case imposing unique demands on validation rigor, traceability, and data integration.

End users such as clinics, diagnostic laboratories, hospitals, and research institutes each face different throughput profiles, capital constraints, and regulatory expectations, which influence adoption curves across the product and technology spectrum. Pathogen classification across fungi, gram negative bacteria, gram positive bacteria, and mycobacteria-along with finer distinctions such as Enterobacteriaceae versus non-Enterobacteriaceae within gram negatives-shapes reagent formulation needs, interpretive criteria, and susceptibility endpoint determination. Understanding these interdependent segmentation layers enables stakeholders to prioritize investments and tailor operational roadmaps

Critical regional insights revealing how regulatory frameworks, infrastructure investment, and manufacturing dynamics are shaping adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics are reshaping procurement preferences, regulatory interaction, and innovation diffusion across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, a strong emphasis on rapid diagnostics and consolidation of centralized testing networks is driving demand for high-throughput automated platforms and integrated informatics that support stewardship initiatives. Laboratories in this region are increasingly focused on rapid turnaround and scalability to manage complex caseloads, which influences choices in instruments and consumables.

Europe, Middle East & Africa present a heterogeneous landscape in which regulatory harmonization efforts, public health priorities, and fiscal constraints create diverse adoption patterns. In parts of this geography, stringent regulatory pathways and centralized procurement models favor validated, standardized solutions; in other areas, decentralized laboratories prioritize cost-effective manual methods and localized reagent solutions. Asia-Pacific demonstrates rapid adoption of automation and molecular hybrid approaches, supported by expanding domestic manufacturing capabilities and strong investment in laboratory infrastructure. This region's scale and manufacturing density also make it a focal point for supply chain reconfiguration and reagent localization efforts.

Across all regions, local regulatory frameworks, reimbursement models, and workforce availability will continue to moderate adoption rates and shape vendor strategies. A clear understanding of regional priorities is essential for tailoring market entry, service models, and distribution partnerships that align with local laboratory operations and clinical governance

Analyzing vendor strategies that prioritize interoperability, consumable-based service models, and regulatory compliance to strengthen clinical and commercial positioning

Leading companies in the antimicrobial susceptibility testing ecosystem are increasingly oriented toward platform interoperability, consumable-driven service models, and data analytics that support clinical decision-making and antimicrobial stewardship objectives. Vendors are enhancing their value propositions by integrating laboratory information systems connectivity, automating interpretive reporting, and offering lifecycle services that reduce the validation burden on end users. These strategic moves prioritize long-term partnerships with clinical networks over single-transaction equipment sales.

Competitive differentiation is also emerging through reagent innovation, such as stabilized kits and simplified media formulations that reduce variability and improve shelf stability across diverse laboratory environments. Manufacturers are investing in modular systems that enable incremental upgrades, protecting capital investments while offering pathways to higher throughput and expanded test menus. Strategic alliances between instrument providers and molecular assay developers are accelerating hybrid workflows that can quickly translate resistance determinant detection into actionable susceptibility guidance.

Finally, companies are intensifying focus on regulatory compliance and localized support, recognizing that rapid service response and robust post-market surveillance are critical for clinical trust. This combination of product innovation, service orientation, and regulatory rigor defines the competitive contours of the market and informs procurement and partnership choices by hospitals, reference laboratories, and research organizations

Actionable strategic recommendations for vendors and laboratories to enhance resilience, interoperability, and clinical impact across susceptibility testing operations

Industry leaders should pursue a balanced strategy that advances automation and molecular integration while preserving flexibility for manual and decentralized testing contexts. Prioritizing investments in modular, interoperable platforms will allow laboratories to scale capabilities without committing to prohibitive capital outlays. Concurrently, establishing robust partnerships with regional reagent manufacturers and distributors will enhance supply resilience and reduce dependency on single-source supply chains.

Operationally, embedding data analytics and stewardship-oriented reporting into platform design will increase clinical impact and support hospital governance objectives. Vendors and laboratories alike should collaborate to standardize data formats and adopt APIs that facilitate integration with electronic health records and infection control systems. From a regulatory and quality perspective, accelerating validation pipelines through pre-approved protocols and harmonized method comparison studies will reduce time to deployment and ensure consistent performance across diverse settings.

Finally, stakeholders should adopt dynamic procurement approaches that incorporate total cost of ownership, service responsiveness, and validation burden into purchasing decisions. By aligning commercial models with clinical workflows and long-term support commitments, industry leaders can unlock sustainable adoption and improved patient outcomes while mitigating operational and supply chain disruptions

Transparent mixed-methods research approach combining literature synthesis, primary stakeholder interviews, and cross-validated data triangulation to ensure analytical rigor

The research methodology combines systematic secondary evidence gathering, targeted primary engagement, and rigorous data triangulation to ensure robust and reproducible insights. Secondary work included a structured review of peer-reviewed literature, regulatory guidance documents, technical white papers, and public procurement policies to establish a factual baseline for technology capabilities, testing standards, and regulatory expectations. This foundational layer informed the design of primary interactions and the framing of analytical hypotheses.

Primary research incorporated structured interviews with laboratory directors, clinical microbiologists, procurement officers, and industry executives to capture operational realities, procurement drivers, and vendor performance perceptions. These engagements were designed to probe validation practices, reagent handling, workflow constraints, and post-market service expectations. Responses were coded and synthesized to identify recurring themes, regional differentiators, and operational pain points that inform practical recommendations.

Quantitative and qualitative inputs were triangulated through cross-validation across data sources, ensuring consistency and identifying outliers. Methodological quality controls included reproducibility checks, analyst peer review, and an audit trail documenting source provenance. This mixed-methods approach supports defensible conclusions and actionable guidance tailored to clinical, research, and commercial stakeholders

Concise conclusion synthesizing technological, operational, and regulatory imperatives to guide sustainable adoption and clinical integration of susceptibility testing

In conclusion, antimicrobial susceptibility testing is evolving from a discrete laboratory task into an integrated clinical asset that supports rapid therapeutic decision-making, stewardship initiatives, and translational research. Technological advances-particularly in automation, molecular hybrid workflows, and software-enabled reporting-are unlocking new efficiencies and clinical value, while also introducing complexity in validation, procurement, and supply chain management. Stakeholders must navigate these trade-offs deliberately, balancing speed, accuracy, and operational feasibility.

Regulatory dynamics, regional manufacturing trends, and trade policy shifts add layers of strategic consideration that influence procurement, service models, and vendor selection. Successful organizations will be those that invest in interoperable platforms, maintain diversified supply relationships, and embed data analytics into clinical workflows to demonstrate measurable impact. Collaboration across clinical, laboratory, and commercial functions will be essential to translate technological potential into reliable, everyday practice.

Ultimately, the path forward requires pragmatic experimentation, rigorous validation, and sustained engagement with end users to ensure that innovations in susceptibility testing deliver improved patient outcomes and enhanced public health preparedness

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of point-of-care rapid susceptibility testing using microfluidic chip technology
  • 5.2. Adoption of AI-driven interpretive algorithms to enhance antimicrobial susceptibility result accuracy
  • 5.3. Growing emphasis on antimicrobial stewardship programs driving demand for rapid AST solutions
  • 5.4. Commercialization of automated high-throughput phenotypic susceptibility testing instruments
  • 5.5. Regulatory approvals for novel antibiotic susceptibility testing biomarkers and assays
  • 5.6. Integration of real-time cloud-based data analytics in clinical AST workflow for decision support
  • 5.7. Development of portable multiplexed AST devices for remote and decentralized healthcare settings
  • 5.8. Rising investment in next-generation sequencing-based resistance profiling for clinical diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Antimicrobial Susceptibility Testing Market, by Product

  • 8.1. Instruments
    • 8.1.1. Bench Top
    • 8.1.2. Walk Away
  • 8.2. Reagents Consumables
    • 8.2.1. Discs
    • 8.2.2. Kits
    • 8.2.3. Media
    • 8.2.4. Strips
  • 8.3. Software

9. Human Antimicrobial Susceptibility Testing Market, by Technology

  • 9.1. Automated Systems
    • 9.1.1. MicroScan Systems
    • 9.1.2. Phoenix Systems
    • 9.1.3. Vitek Systems
  • 9.2. Disk Diffusion
  • 9.3. Gradient Strip
  • 9.4. Microdilution
  • 9.5. Molecular Methods

10. Human Antimicrobial Susceptibility Testing Market, by Test Type

  • 10.1. Automated Testing
  • 10.2. Manual Testing
    • 10.2.1. Agar Dilution
    • 10.2.2. Broth Microdilution
    • 10.2.3. Disk Diffusion
    • 10.2.4. Gradient Strip

11. Human Antimicrobial Susceptibility Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Pharmaceutical
  • 11.3. Research

12. Human Antimicrobial Susceptibility Testing Market, by End User

  • 12.1. Clinics
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Human Antimicrobial Susceptibility Testing Market, by Pathogen

  • 13.1. Fungi
  • 13.2. Gram Negative Bacteria
    • 13.2.1. Enterobacteriaceae
    • 13.2.2. Non Enterobacteriaceae
  • 13.3. Gram Positive Bacteria
  • 13.4. Mycobacteria

14. Human Antimicrobial Susceptibility Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Antimicrobial Susceptibility Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Antimicrobial Susceptibility Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. bioMerieux SA
    • 17.3.2. Thermo Fisher Scientific Inc.
    • 17.3.3. Becton, Dickinson and Company
    • 17.3.4. Danaher Corporation
    • 17.3.5. Siemens Healthineers AG
    • 17.3.6. Accelerate Diagnostics Inc.
    • 17.3.7. Bruker Corporation
    • 17.3.8. QIAGEN N.V.
    • 17.3.9. F. Hoffmann-La Roche AG
    • 17.3.10. Luminex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)